Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A10930" target="_blank" >RIV/00216208:11110/11:10930 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/11:10930

Result on the web

<a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2010.01533.x/full" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0609.2010.01533.x/full</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study

Original language description

This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible forhigh-dose therapy who received bortezomib plus melphalan-prednisone.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European Journal of Haematology

ISSN

0902-4441

e-ISSN

—

Volume of the periodical

2011/86

Issue of the periodical within the volume

1

Country of publishing house

DK - DENMARK

Number of pages

9

Pages from-to

23-31

UT code for WoS article

000285302200003

EID of the result in the Scopus database

—